Drug Name | Maker | Disease Category | Purpose | 2006 | 2009 | DrugBank |
---|
ABT-263 | Abbott | Cancer | Lymphoma, etc. | ? | PI | 0 |
ABT-333 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
ABT-143 | Abbott | Cardiovascular | Cholesterol, a statin drug | ? | PIII | 0 |
ABT-335 | Abbott | Cardiovascular | Cholesterol, a statin drug | ? | PIII | 0 |
ABT-510 (Thrombospondin Analogue) | Abbott | Cancer | Head, neck | ? | PII | 0 |
ABT-751 | Abbott | Cancer | non-small cell lung | ? | PI-PII some studies terminated | 0 |
ABT-894 | Abbott | Diabetes | Diabetic Neuropathies | ? | PII | 0 |
ABT-450 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
ABT-874 | Abbott | Autoimmune | Psoriasis | ? | PIII |
ABT-888 | Abbott | Cancer | Leukimia, Chronic Myeloproliferative Disorders | ? | PI, PII | 0 |
ABT-869 | Abbott | Cancer | Solid tumor, advanced, metastatic | ? | PI PII | 0 |
ABT-102 | Abbott | ? | ? | ? | PI | 0 |
ABT-089 | Abbott | Neurological | ADHD | ? | PII some terminated | 0 |
ABT-126 | Abbott | Neurological | Alzheimer's disease | ? | PI | 0 |
ABT-072 | Abbott | Infectious, virus | HCV | ? | PI | 0 |
Cetrorelix Pamoate | AEterna Zentaris | Prostate | Benign prostatic hyperplasia | ? | PIII | 0 |
CPI-300 | IntelGenx and Cary Pharmaceuticals | Neurological | antidepressant | ? | ? | 0 |
Tigecycline (Tygacil) | Wyeth | Infectious, Antibiotic | MRSA | approved | approved | 00560DB |
Mecasermin (Increlex) | Tercia | Hormone | Growth factor, synthetic IGF-1 | approved | approved | 01277DB |
Dalbavancin (Zeven) | Pfizer | Infectious, Antibiotic | Gram+ (MRSA, MRSE) | Awaiting regulatory decision | PIII active | 0 |
Denosumab (AMG 162) | Amgen | Osteoporosis | Treats osteoporosis | Late-stage trial | PIII active | 0 |
Dimebolin, (Dimebon) | Medivation | Neurological | Alzheimer's disease | ? | PI PII | 0 |
Gardasil | Merck | Infectious, virus | Vaccine prevents hpv/cervical cancer | Late-stage trial | approved | 0 |
Ranibizumab (Lucentis) | Genentech, Novartis | Vision | Treats macular degeneration | Late-stage trial | approved | 01270DB |
Belimumab (Benlysta or LymphoStat-B) | Human Genome Sciences, GlaxoSmithKline | Autoimmune | Treats lupus, rheumatoid arthritis | Mid-stage trial | PII active | 0 |
Maraviroc | Pfizer | Infectious, virus | Treats HIV/AIDS | Late-stage trial | approved | 04835DB |
Aflibercept (AVE005, VEGF-trap) | Regeneron | Cancer | Ovarian cancer | ? | PII PIII | 0 |
Stamulumab (MYO-029) | Wyeth | Muscular dystrophy | Treats muscular dystrophy | Early-stage clinical trial | PII | 0 |
Ciliary Neurotrophic Factor implant (NT-501) | Neurotech USA | Vision | RP, AMD, source of CNTF | ?? | PIII active | 0 |
VEGF structural antagonist implant (NT-503) | Neurotech USA | Vision | wet AMD, source of VEGF antagonist | ?? | ?? | 0 |
Disufenton sodium (NXY-059) | Renovis, AstraZeneca | Neurological | Stroke | Late-stage trial | PIII completed | 0 |
Varenicline (Champix) | Pfizer | Neurological | Smoking addiction | Late-stage trial | approved | 01273DB |
Tarenflurbil (Flurizan) | Myriad Genetics | Neurological | Alzheimer's disease | Late-stage trial | abandoned | 0 |
Gaboxadol | Merck, Lundbeck | Neurological | Sleeplessness | Late-stage trial | abandoned | 0 |
Indiplon | Neurocrine Biosciences, Pfizer | Neurological | Sleeplessness | Late-stage trial | abandoned? | 0 |
Natalizumab(Tysabri, Antegren) | Biogen Idec, Elan | Neurological | Multiple sclerosis | FDA-approved but withdrawn | In use under observation | 00108DB |
Ruboxistaurin (Arxxant) | Eli Lilly | Diabetes | Treat complications | Late-stage trial | PIII active | 0 |
Tesaglitazar (Galida) | AstraZeneca | Diabetes | Lower blood sugar and cholesterol | Late-stage trial | abandoned | 0 |
Vildagliptin (Galvus) | Novartis | Diabetes | Control blood sugar | Late-stage trial | abandoned 2008 | 0 |
Sitagliptin (Januvia, MK-0431) | Merck | Diabetes | Control blood sugar | Late-stage trial | approved | 01261DB |
Darapladib (480848 ) | GlaxoSmithKline | Cardiovascular | Prevent atherosclerosis and heart attack | Late-stage trial | Darapladib | 0 |
Rimonabant (Acomplia) | Sanofi-Synthelabo | Cardiovascular | Combat obesity; reduce risk of heart disease | Awaiting regulatory decision | approved | 06155DB |
AGI-1067 | AtheroGenics | Cardiovascular | Combat artery inflammation | Late-stage trial | abandoned | 0 |
Alfimeprase | Nuvelo | Cardiovascular | Clot-buster | Late-stage trial | abandoned | 0 |
Celacade | Vasogen | Cardiovascular | Treat heart failure | Late-stage trial | Celacade | 0 |
Veliflapon (DG031) | DeCode Genetics | Cardiovascular | Combat artery inflammation | Mid-stage trial | PIII suspended ??deCODE in bankruptcy | 0 |
ETC-216 | Pfizer, Esperion Therapeutics | Cardiovascular | Remove cholesterol from arteries | Mid-stage trial | ?? ETC-216 absent | 0 |
ETC-1002 | Pfizer, Esperion Therapeutics | Cardiovascular | inhibit fatty acid synthesis, promote fatty acid degredation | ?? | Candidates | 0 |
Lipitor-torcetrapib | Pfizer | Cardiovascular | Raise good cholesterol | Late-stage trial | Torcetrapib abandoned | 0 |
CP-690,550 ( JAK-3 inhibitor) | Pfizer | Autoimmune | Rheumatoid Arthritis | ? | PIII |
LY518674 (PPAR alpha agonist) | Eli Lilly, Ligand Pharmaceuticals | Cardiovascular | Raise good cholesterol, lower triglycerides | Mid-stage trial | ?? | 0 |
Aliskiren (Rasilez) | Novartis | Cardiovascular | Reduce high blood pressure | Late-stage trial | approved | 01258DB |
Sitaxentan (Thelin) | Pfizer, Encysive Pharmaceuticals | Cardiovascular | Treat pulmonary hypertension | Awaiting regulatory decision | 0 approved outside US FDA letter | 0 |
Acapodene | GTx | Cancer | Prostate cancer prevention | Late-stage trial | approved | 00539DB |
Ridaforolimus (AP23573) | Ariad Pharmaceuticals | Cancer | Sarcoma | Mid-stage trial | recruiting PIII | 0 |
Abatacept (Orencia) | Bristol-Myers Squibb | Autoimmune | Rheumatoid arthritis | ? | PIII | 0 |
Dasatinib | Bristol-Myers Squibb | Cancer | Leukemia | Awaiting regulatory decision | approved | 01254DB |
Ipilimumab | Medarex, Bristol-Myers Squibb | Cancer | Melanoma | Late-stage trial | active PIII | 0 |
Panitumumab | Amgen | Cancer | Colon cancer, other tumors | Awaiting regulatory decision | approved | 01269DB |
Vatalanib (PTK-787) | Novartis, Schering | Cancer | Colon cancer | Late-stage trial | active PIII | 0 |
Provenge | Dendreon | Cancer | Prostate cancer | Late-stage trial | active PIII | 0 |
Telcyta (TLK286) | Telik | Cancer | Ovarian cancer | Late-stage trial | active PIII | 0 |
Ticilimumab | Pfizer | Cancer | Melanoma | Mid-stage trial | active PIII | 0 |
Lapatinib | GlaxoSmithKline | Cancer | Breast cancer, bladder cancer | Late-stage trial | approved | 01259DB |
Bavituximab | Perigrine Pharmaceuticals | Cancer | Solid tumer | ? | PI PII | 0 |
Cotara 131I-chTNT-1/B MAb | Perigrine Pharmaceuticals | Cancer | Glioblastoma | ? | PI PII | 0 |
Elesclomol | Synta | Cancer | Melanoma, metastatic | ? | PII some suspended | 0 |
Fostamatinib disodium (R935788) | Rigel | Autoimmune | Rheumatoid arthritis | ? | PII | 0 |
Palladia | Pfizer | Cancer | For Dogs | ? | 0 |
Arzerra | Genmab, GlaxoSmithKline | Cancer | lymphocytic leukemia | Collab. initiated | PII | 0 |
Apremilast | Celgene | autoimmune | psoriatic arthritis | ? | PII | 0 |
Aldesleukin (Proleukin) | Novartis | Cancer | Metastatic melanoma, metastatic kidney | ? | PI PII | 0 |
Darusentan | Gilead Sciences | Cardiovascular | Hypertension | ? | PIII | 0 |
Stimuvax (BLP25) | Oncothyreon, Merk Serono | Cancer | Carcinoma, Non-Small-Cell Lung; breast cancer | ? | PII PII | 0 |
Ocrelizumab | Genentech | Autoimmune | Rheumatoid arthritis | ? | PII | 0 |
Cixutumumab | ImClone | Cancer | Solid tumors | ? | PII | 0 |
NVA237 | Novartis, Vectura | Pulmonary | chronic obstructive pulmonary disease | ? | PII PIII | 0 |
SEP-225289 | Sepracor | Neurological | Depressive disorder, major | ? | PII | 0 |
Lu AA24530 | Lundbeck | Neurological | Depressive disorder, major | ? | PII | 0 |
PRO-040201 | Tekmira Pharmaceuticals Corporation | Cardiovascular | Hypercholesterolemia | ? | PI | 0 |
TB-402 | ThromboGenics, BioInvent | Cardiovascular | Blood thinner | ? | PII | 0 |
Saxagliptin (Onglyza, BMS-477118) | Bristol-Meyers Squibb | Metabolic | Diabetes, type 2 | ? | PIII | 0 |